Skip to main content
OpenTrials
Completed

NCT Number: NCT05825755

Multicenter Trial for the Validation of Vitalera Platform

Vitalera has implemented a cloud platform for the telemonitoring of chronic patients through portable medical devices and an alarm-based system that issues health alerts when a patient's biomedical measurement is outside a predefined clinical range. The platform frees doctors and caregivers from reviewing individual patient data for abnormalities, speeding up the decision-making process and reducing hospital visits. With this study we intend to validate the efficacy of the app for patients and digital platform for medical professionals, evaluating the increase in the quality of life of patients and measuring the reduction in the incidence of the main critical events of HF. In addition, the study will validate the new API interoperability standards and platform architecture and will assess the usability of the platform by delivering satisfaction questionnaires to patients and professionals at the end of the study.

This study is being carried out within the framework of a European project promoted by the European Innovation Council (EIC).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital de Dénia, Denia, Alacant, Spain

Loading trial locations.

About this study

This is a randomized controlled trial involving a Spanish network of hospitals. The study consists of continuous remote patient monitoring using vitalera's digital platform and the supplied devices (blood pressure monitor, wearable, scale and oximeter). For 3 months, a total of 250 patients suffering from HF will have their physiological constants monitored.

Patients will be included in the study based on the eligibility criteria and must complete the informed consent provided. Each hospital will decide when to include their patients according to their particular clinical practice. The recruitment period is defined as 3 months. That means patients will be incorporated into the study from its start until the third month. The last subject included in the study will then finish the study after six months from the first day of the study. Medical professionals from each hospital will be in charge of recruiting the participants. The recruitment rate is specific for each hospital, and it may vary depending on the month.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Heart failure (HF) patients with NYHA Functional Class >= II (according to 2021 EU guidelines).
  • Patients older than 18 years old.
  • Patients who have suffered an acute decompensation of HF (first and recurrent) in the 30 days prior to enrollment in the study.
  • NT-pro BNP ≥300 pg/ml at the moment of hospitalization for patients without ongoing atrial fibrillation/flutter. If ongoing atrial fibrillation/flutter, NT-pro BNP must be ≥600 pg/mL
  • Patients must have had an echocardiogram during their HF hospitalization or in the previous 12 months.
  • Prior to initiating any procedures, the hospital will ensure that the patient obtains an informed consent document, if applicable.
  • All patients will be eligible regardless of the level of LVEF: HFrEF, HFmrEF, and HFpEF.

Exclusion criteria

  • Oncology patients with metastasis or with chemotherapy treatment ongoing
  • Patients participating in other studies or trials.
  • Patients not willing to participate.
  • Patients over 150 kg
  • Patients who do not use Catalan, Spanish, English, Portuguese, Italian, Dutch, German, Swedish, Hungarian, Romanian or French.
  • Patients without a mobile phone
  • Patients without internet connexion
  • Patients with moderate or severe cognitive impairment without a competent caregiver
  • Patients with serious psychiatric illness
  • Patients with planned cardiac surgery
  • Patients with planned heart transplantation or LVAD implant

Treatment and study plan

vitalera telemonitoring platform

Other

Patients will be followed-up with measurements from medical devices and health questionnaires delivered through the app

Primary outcomes

  1. Change in Quality of Life Scale Between Baseline and 3-months Follow-up

    Time frame: 3 months

    Quality of life measured with the Minnesota Living with Heart Failure scale. Scale from 0 to 105. The lower the score the better outcome.

  2. Change in the Proportion of Treatment Adherent Patients Between Baseline and 3-months Follow-up.

    Time frame: 3 months

    Change in the proportion of patients adherent to treatment measured with SMAQ between start and end of the study. This questionnaire consists of six questions that evaluate different aspects of patient compliance with treatment: forgetfulness, routine, adverse effects, and a quantification of omissions. A patient is classified as non-compliant (non-adherent) if he/she responds to any of the questions with a non-adherence answer, and in terms of quantification, if the patient has lost more than two doses during the last week or has not taken medication during more than two complete days during the last three months.

    Then we compute the proportion of adherent patients at baseline and 3-months follow-up and compute the change in proportion.

  3. Change in Sel-care Behaviour Scale Between Baseline and 3-months Follow-up

    Time frame: 3 months

    Patient's self-care behavior measured with The European Heart Failure Self-Care Behavior Scale. Scale from 9 to 45. The higher the score the poorer self-care.

Secondary outcomes

  1. Mortality From Any Cause

    Time frame: 3 months

    Number of deaths during the study period

  2. Number of Hospital Readmissions

    Time frame: 3 months

    Total number of hospitalizations

  3. Number of Visits to the Emergency Room Due to HF Decompensation

    Time frame: 3 months

    Total number of visits with intravenous decongestive therapy

  4. Number of Emergency Visits for CV Causes

    Time frame: 3 months

    Total number of visits due to cardiovascular causes

Sponsors and collaborators

Lead sponsor

humanITcare

Network

Registry information

Official study title

Randomized Controlled Multicenter Trial for the Validation of Vitalera Platform

Acronym: VAL-HIC

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Apr 24, 2023
Registry last updated
Mar 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.